Island Pharmaceuticals Ltd (AU:ILA)
ASX:ILA
Want to see AU:ILA full AI Analyst Report?
ILA Stock Chart & Stats
AU$0.44
<AU$0.01(1.74%)
At close: 4:00 PM EST
AU$0.44
<AU$0.01(1.74%)
Day’s Range― - ―
52-Week RangeAU$0.13 - AU$0.63
Previous CloseN/A
Volume208.69K
Average Volume (3M)781.24K
Market Cap
AU$103.57M
Enterprise ValueAU$95.66M
Total Cash (Recent Filing)AU$6.87M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-0.90
Next Earnings
Aug 27, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding295,916,700
10 Day Avg. Volume388,484
30 Day Avg. Volume781,243
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)3.39
Price to Sales (P/S)204.10
P/FCF Ratio-8.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Debt, Stronger Equity BaseZero financial debt and a materially higher equity base materially reduce solvency and refinancing risk. This structural strength gives management flexibility to fund clinical programs or seek partnerships without immediate leverage pressure, improving long-term operational optionality.
Clear Antiviral R&D FocusA focused antiviral development strategy concentrates scientific expertise and assets in a durable therapeutic niche. Specialization can create competitive advantages for partnerships, targeted trial design, and licensing opportunities that persist across funding cycles and support long-run value capture.
Improving Cash Burn TrendA modest improvement in cash burn indicates tighter operational control and incremental extension of runway. If sustained, reduced negative cash flow lowers near-term capital needs and gives management more time to advance programs or negotiate deals without immediate dilutive financing.
Bears Say
Sharp Revenue DeclineA roughly 70% revenue drop erodes internal funding capacity and signals commercial or partnership setbacks. For a development-stage biotech, declining receipts reduce optionality, increase reliance on external capital, and weaken the firm's ability to sustain R&D momentum over the medium term.
Persistent Negative Operating Cash FlowOngoing negative operating and free cash flow indicate the business consumes cash to fund operations and trials. This structural drain necessitates frequent funding rounds or partnerships, raising dilution risk and constraining long-term strategic investments even with low reported debt.
Deep Net Losses And Weak MarginsSustained deep losses and weak margins suppress returns on equity and signal that operations are not self-sustaining. For shareholders, repeated losses imply future equity raises or deal-dependent value realization, prolonging the timeline to profitability and adding structural execution risk.
Island Pharmaceuticals Ltd News
ILA FAQ
What was Island Pharmaceuticals Ltd’s price range in the past 12 months?
Island Pharmaceuticals Ltd lowest share price was AU$0.13 and its highest was AU$0.63 in the past 12 months.
What is Island Pharmaceuticals Ltd’s market cap?
Island Pharmaceuticals Ltd’s market cap is AU$103.57M.
When is Island Pharmaceuticals Ltd’s upcoming earnings report date?
Island Pharmaceuticals Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 99 days.
How were Island Pharmaceuticals Ltd’s earnings last quarter?
Island Pharmaceuticals Ltd released its earnings results on Feb 25, 2026. The company reported -AU$0.019 earnings per share for the quarter, missing the consensus estimate of -AU$0.005 by -AU$0.014.
Is Island Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Island Pharmaceuticals Ltd’s price is currently Overvalued.
Does Island Pharmaceuticals Ltd pay dividends?
Island Pharmaceuticals Ltd does not currently pay dividends.
What is Island Pharmaceuticals Ltd’s EPS estimate?
Island Pharmaceuticals Ltd’s EPS estimate is -0.01.
How many shares outstanding does Island Pharmaceuticals Ltd have?
Island Pharmaceuticals Ltd has 295,916,700 shares outstanding.
What happened to Island Pharmaceuticals Ltd’s price movement after its last earnings report?
Island Pharmaceuticals Ltd reported an EPS of -AU$0.019 in its last earnings report, missing expectations of -AU$0.005. Following the earnings report the stock price went up 1.408%.
Which hedge fund is a major shareholder of Island Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in AU:ILA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Island Pharmaceuticals Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ILA Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.00%
12-Months-Change
Fundamentals
Return on Equity
-100.58%
Trailing 12-Months
Asset Growth
86.01%
Trailing 12-Months
Company Description
Island Pharmaceuticals Ltd
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing approximately four and a half thousand molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was founded in 2017 and is based in Camberwell, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Prescient Therapeutics Limited
―
Starpharma Holdings Limited
―
AnteoTech Ltd
―
Neuroscientific Biopharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---